Elza DeBruin

Featured in: Favicon

Articles

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models | npj Breast Cancer

Aug 18, 2023 | nature.com | Lorna Hopcroft |Stuart Williamson |Susana Ros |Larissa S. Carnevalli |Elza DeBruin

Correction to: npj Breast Cancer https://doi.org/10.1038/s41523-023-00571-w, published online 05 August 2023In this article the author name Scott Hoffmann, was incorrectly written as Scott Hoffman. The original article has been corrected.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models - npj Breast Cancer

Aug 5, 2023 | nature.com | Stuart Williamson |Susana Ros |Lorna Hopcroft |Larissa S. Carnevalli |Elza DeBruin

Cell culture and reagentsAll cell lines were authenticated using DNA fingerprinting short-tandem repeat (STR) assays. To generate resistant cell populations, parental cell lines were exposed to escalating concentrations of palbociclib over 4–6 months. T47D cells were cultured up to a final dose of 3 μM, which generated two PalboR cell pools (named T47D RB− & T47D CDK6H).

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.